PCPC3 and its members are extremely pleased to learn that a key advisory group to Medicare has recommended that the Centers for Medicare & Medicaid Services (CMS) step back from a proposal, initially put forward late in 2015, to penalize physicians financially for performing tests for risk of prostate cancer using the prostate-specific antigen (PSA) test.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Several individual members of PCPC3 contributed formal and detailed comments to CMS stating their strong opposition to this proposal, including:
- The National Alliance of State Prostate Cancer Coalitions (NASPCC)
- Prostate Cancer International (PCaI)
- The Prostate Conditions Education Council (PCEC)
- The Prostate Health Education (PHEN) and
- Us TOO International
While the value of the PSA test in screening for prostate cancer has been a controversial issue for many years, there is no doubt whatsoever that, at this time, it remains a low-cost and simple blood test that offers concerned men and their families valuable information about their possible risk for diagnosis with the commonest form of cancer found among men in America.
PCPC3 and its members are pleased to have been able to take concerted action, along with others, such as the American Urological Association, to push back successfully against this poorly thought out proposal.
PCPC3 further recognizes that the U.S. Preventive Services Task Force (USPSTF) is currently re-evaluating its May 2012 recommendation that the PSA test should not be routinely used at all as a tool to screen men for risk of prostate cancer.
PCPC3 — the patient-centered prostate cancer collaborative coalition — is a group of independent, not-for-profit, patient-centric organizations whose primary goals include the education and support of men diagnosed with prostate cancer, their family members and care-givers, and all men at risk for prostate cancer. For more information about PCPC3, please see the PCPC3 web site.